Breaking Down SG&A Expenses: Novartis AG vs Merus N.V.

A Tale of Two Companies: SG&A Expenses of Novartis AG and Merus N.V.

In the ever-evolving pharmaceutical industry, understanding the financial strategies of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent companies: Novartis AG and Merus N.V., from 2014 to 2023.

Novartis AG: A Steady Giant

Novartis AG, a Swiss multinational, consistently allocated a significant portion of its budget to SG&A expenses, averaging around $14.5 billion annually. Despite a slight decline in 2023, the company's strategic investments in marketing and administration have been pivotal in maintaining its market dominance.

Merus N.V.: A Rising Star

In contrast, Merus N.V., a smaller biotech firm, exhibited a remarkable growth trajectory. From a modest $3.9 million in 2014, its SG&A expenses surged by over 1,400% to nearly $60 million in 2023, reflecting its aggressive expansion and market penetration strategies.